| Primary | Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment | The number of participants who received ITP therapies for first-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| | | Title | Denominators | Categories |
|---|
| Corticosteroids | | | | IVIG (Intravenous immunoglobulin) | | | | Rituximab | | |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Second-line Treatment. | The number of participants who received ITP therapies for second-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Third-line Treatment. | The number of participants who received ITP therapies for third-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Fourth-line Treatment. | The number of participants who received ITP therapies for fourth-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Fifth-line Treatment | The number of participants who received ITP therapies for fifth-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Sixth-line Treatment. | Assessed the number of participants who received ITP therapies for sixth-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies for Seventh or Greater-line Treatment. | The number participants who received ITP therapies as seventh or greater-line treatment during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Primary | The Number of Participants Utilizing ITP Therapies: Treatments With Unknown Starting Date. | The number of participants who received ITP therapies for treatments with unknown starting date during either the retrospective or prospective phases of the study. | All enrolled participants | Posted | | Number | | Participants | | Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12). | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Change From Baseline to Month 12 in Quality of Life Measured by the ITP-Patient Assessment Questionnaire (PAQ) | The Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ) was developed to assess disease-specific quality of life (QoL) in adults with ITP. It is a 44-item questionnaire that includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work. Scores for each scale range from 0 (worst) to 100 (best). | The Patient Reported Outcome (PRO) Analysis Set includes all participants who completed at least one questionnaire during the prospective observation period. | Posted | | Mean | Standard Deviation | Units on a scale | | Baseline to month 12 during prospective data collection phase | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Change From Baseline to Month 12 in Health-related Quality of Life Assessed by EuroQol Visual Analog Scale (EQ-5D VAS) | The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' (score = 100) and 'Worst imaginable health state' (score = 0). | The Patient Reported Outcome (PRO) Analysis Set includes all subjects who completed at least one questionnaire during the prospective observation period. | Posted | | Mean | Standard Deviation | Units on a scale | | Baseline to Month 12 during prospective data collection phase | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Change From Baseline to Month 12 in Treatment Satisfaction | Participant satisfaction with treatment was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), an 11-item questionnaire providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. TSQM Scale scores range from 0 to 100 with higher scores indicating more satisfaction with treatment. | The Patient Reported Outcome (PRO) Analysis Set includes all participants who completed at least one questionnaire during the prospective observation period. | Posted | | Mean | Standard Deviation | Units on a scale | | Baseline to Month 12 during prospective data collection phase | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Number of Participants Receiving Drug Therapies for Treatment of ITP During the Prospective Phase | The number of participants who received drug therapies for the treatment of ITP during the prospective phase of the study. Use of multiple medications by the same participants is possible. | All enrolled participants who completed at least 1 observational study visit during the prospective phase. | Posted | | Number | | Participants | | 12 months (prospective data collection phase) | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Duration of Exposure to ITP Medication | Duration of exposure to each ITP medication measured from enrollment until the end of the 12-month data collection phase. | All enrolled participants who completed at least 1 observational study visit during the prospective phase. N=number of participants using each medication. | Posted | | Mean | Standard Deviation | Months | | 12 months (prospective data collection phase) | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| |
| Secondary | Number of Participants Requiring Splenectomy | The number of participants who required a splenectomy during the 12-month prospective phase of the study. | All enrolled participants who completed at least 1 observational study visit during the prospective phase. | Posted | | Number | | Participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | Patients With ITP | Patients diagnosed with ITP were followed prospectively for a period of 12 months. |
| | |